Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Colorcon
Boehringer Ingelheim
Medtronic
McKinsey

Last Updated: January 29, 2022

Volunteer for clinical trials for VOSEVI at ClinicalTrialExchange

DrugPatentWatch Database Preview

VOSEVI Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Vosevi patents expire, and when can generic versions of Vosevi launch?

Vosevi is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eighteen patents protecting this drug.

This drug has six hundred and two patent family members in forty-eight countries.

The generic ingredient in VOSEVI is sofosbuvir; velpatasvir; voxilaprevir. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sofosbuvir; velpatasvir; voxilaprevir profile page.

DrugPatentWatch® Generic Entry Outlook for Vosevi

Vosevi was eligible for patent challenges on June 28, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 1, 2037. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for VOSEVI
Drug Prices for VOSEVI

See drug prices for VOSEVI

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VOSEVI
Generic Entry Date for VOSEVI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VOSEVI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Partners in HealthPhase 4
Gilead SciencesPhase 3

See all VOSEVI clinical trials

US Patents and Regulatory Information for VOSEVI

VOSEVI is protected by twenty US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VOSEVI is ⤷  Try it Free.

This potential generic entry date is based on patent ⤷  Try it Free.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VOSEVI

Combination formulation of three antiviral compounds
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Combination formulation of two antiviral compounds
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Antiviral compounds
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Nucleoside phosphoramidates
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Nucleoside phosphoramidates
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Compositions and methods for treating hepatitis C virus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Antiviral compounds
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Antiviral compounds
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Nucleoside phosphoramidates
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Inhibitors of hepatitis C virus
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR

Nucleoside phosphoramidate prodrugs
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR

Antiviral compounds
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

FDA Regulatory Exclusivity protecting VOSEVI

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try it Free

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for VOSEVI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2203462 14C0082 France ⤷  Try it Free PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2430014 2016C/006 Belgium ⤷  Try it Free PRODUCT NAME: LEDIPASVIR/SOFOSBUVIR; AUTHORISATION NUMBER AND DATE: EU/1/14/958 20141118
2203462 PA2014040,C2203462 Lithuania ⤷  Try it Free PRODUCT NAME: SOFOSBUVIRAS; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116
2203462 214 5029-2014 Slovakia ⤷  Try it Free PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Harvard Business School
Baxter
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.